Ambrisentan: a guide to its use in pulmonary arterial hypertension

被引：0
|
作者：
机构：
来源：
Drugs & Therapy Perspectives | 2009年 / 25卷 / 7期
关键词：
D O I：
10.2165/0042310-200925070-00001
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1 / 5
页数：4
相关论文
共 50 条
  • [21] Safety and Efficacy of Ambrisentan in the Treatment of Pulmonary Arterial Hypertension
    Valerio, Christopher J.
    Kabunga, Peter
    Coghlan, John G.
    CLINICAL MEDICINE INSIGHTS-THERAPEUTICS, 2009, 1 : 541 - 556
  • [22] Ambrisentan ± tadalafil in WHO functional class II/III pulmonary arterial hypertension: a guide to its use in the EU (vol 34, pg 289, 2018)
    Lyseng-Williamson, Katherine A.
    Behr, Jurgen
    DRUGS & THERAPY PERSPECTIVES, 2019, 35 (01) : 47 - 47
  • [23] THE COST EFFECTIVENESS OF AMBRISENTAN FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION IN IRELAND
    Redmond, S.
    Bozkaya, D.
    VALUE IN HEALTH, 2009, 12 (07) : A329 - A329
  • [24] Ambrisentan therapy for pulmonary arterial hypertension: A comparison by path etiology
    Badesch, David B.
    CHEST, 2007, 132 (04) : 488S - 489S
  • [25] Pharmacokinetics of ambrisentan in a patient with Pulmonary Arterial Hypertension and a total gastrectomy
    Abston, Eric
    Farber, Harrison W.
    PULMONARY PHARMACOLOGY & THERAPEUTICS, 2019, 57
  • [26] Sildenafil versus Ambrisentan in a Rat Model of Pulmonary Arterial Hypertension
    Senese, P. B.
    Martinez, T.
    Doherty, K. R.
    Bi, J.
    Wang, H.
    Zammit, M.
    Gralinski, M. R.
    INTERNATIONAL JOURNAL OF TOXICOLOGY, 2020, 39 (01) : 76 - 76
  • [27] Sildenatil versus ambrisentan in a rat model of pulmonary arterial hypertension
    Senese, P. B.
    Martinez, T.
    Doherty, K. R.
    Bi, J.
    Wang, H.
    Zammit, M. D.
    Gralinski, M. R.
    Hock, F.
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2020, 393 (SUPPL 1) : 63 - 64
  • [28] Impact of transition from Sitaxsentan to Ambrisentan in Pulmonary Arterial Hypertension
    Safdar, Z.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2010, 181
  • [29] Ambrisentan for Pulmonary Arterial Hypertension Due to Congenital Heart Disease
    Zuckerman, Warren A.
    Leaderer, Derek
    Rowan, Cherise A.
    Mituniewicz, Johnell D.
    Rosenzweig, Erika Berman
    AMERICAN JOURNAL OF CARDIOLOGY, 2011, 107 (09): : 1381 - 1385
  • [30] Effect of transition from sitaxsentan to ambrisentan in pulmonary arterial hypertension
    Safdar, Zeenat
    VASCULAR HEALTH AND RISK MANAGEMENT, 2011, 7 : 119 - 124
12345